Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: Involvement of Kv potassium channels

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Campolongo, Patrizia ^a   Ratano, Patrizia ^a   Ciotti, Maria Teresa ^b   Florenzano, Fulvio ^b,c   Nori, Stefania Lucia ^d   Marolda, Roberta ^b   Palmery, Maura ^a   Rinaldi, Anna Maria ^e   Zona, Cristina ^e,f   Possenti, Roberta ^e   Calissano, Pietro ^c   Severini, Cinzia ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV2.1; POTASSIUM CHANNEL KV4.2; SUBSTANCE P; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HIPPOCAMPUS; KV1.4 POTASSIUM CHANNEL; MALE; MAZE LEARNING; PEPTIDE FRAGMENTS; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE P;

EID: 84891888722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078036     Document Type: Article

References (64)

1. Lallemend F, Lefebvre PP, Hans G, Rigo JM, Van de Water TR, et al. (2003) Substance P protects spiral ganglion neurons from apoptosis via PKC-Ca2+-MAPK/ERK pathways. J Neurochem 87: 508-21.
2. Salthun-Lassalle B, Traver S, Hirsch C, Michel PP (2005) Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. Mol Pharmacol 68: 1214-24.
3. Amadoro G, Pieri M, Ciotti T, Carunchio I, Canu N, et al. (2007) Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium current. Neuropharmacology 52: 1366-77.
4. Quigley BJ Jr, Kowall NW (1991) Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience 41: 41-60.
5. Waters SM, Davis TP (1997) Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type. Ann NY.Acad Sci 814: 30-39.
6. Raffa RB (1998) Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neurosci Bioehav.Rev 22: 789-813.
7. Jiménez-Corral C, Morán-Sánchez JC, Alonso-Navarro H (2006) Neuropeptides in Alzheimer's disease. Rev Neuro 42: 354-9.
8. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54: 285-322.
9. Selkoe DJ (1989) Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58: 611-12.
10. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13; 1676-87.
11. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, et al. (2007) Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to A25-35 oligomers, S100 and neurotransmitters. J Neuroimmunol 186: 181-92.
12. Kubo T, Nishimura S, Kumagae Y, Kaneko I (2002) In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70: 474-83.
13. Kaneko I, Morimoto K, Kubo T (2001) Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]betaamyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 104: 1003-11.
14. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, et al. (1995) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-65.
15. Zussy C, Brureau A, Delair B, Marchal S, Keller E, et al. (2011) Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid b fragment in rats. Am J Pathol 179: 315-34.
16. Zussy C, Brureau A, Keller E, Marchal S, Blayo C, et al. (2013) Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-b Peptide Injection in Rats. PLoS One 8, e53117.
17. Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G (2012) Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol 46: 572-87.
18. Maurice T, Lockhart BP, Su TP, Privat A (1996) Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Res 731: 249-53.
19. Delobette S, Privat A, Maurice T (1997) In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol 319: 1-4.
20. Hasenöhrl RU, Souza-Silva MA, Nikolaus S, Tomaz C, Brandao, et al. (2000) Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 34: 272-80.
21. Huston JP, Oitzl MS (1989) The relationship between reinforcement and memory: parallels in the rewarding and mnemonic effects of the neuropeptide substance P. Neurosci Biobehav Rev 13: 171-180.
22. Kertes E, László K, Berta B, Lénárd L (2009) Effects of substance P microinjections into the globus pallidus and central nucleus of amygdala on passive avoidance learning in rats. Behav Brain Re 198: 397-403.
23. Liu XM, Shu SY, Zeng CC, Cai YF, Zhang KH, et al. (2011) The Role of Substance P in the Marginal Division of the Neostriatum in Learning and Memory is Mediated Through the Neurokinin 1 Receptor in Rats. Neurochem Res 36: 1896-902.
24. Hasenöhrl RU, Huston JP, Schuurman T (1990) Neuropeptide substance P improves water maze performance in aged rats. Psychopharmacology (Berl) 101: 23-6.
25. Hasenöhrl RU, Frisch C, Nikolaus S, Huston JP (1994) Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. Behav Neural Biol 62: 110-20.
26. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA (1991) An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 88: 7247-51.
27. Furukawa K, Barger SW, Blalock EM, Mattson MP (1996) Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloidprecursor protein. Nature 379: 74-8.
28. Yu SP, Yeh CH, Sensi SL, Gwag BJ, Canzoniero LM, et al. (1997) Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 278: 114-7.
29. Ramsden M, Plant LD, Webster NJ, Vaughan PF, Henderson Z, et al. (2001) Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurones. J Neurochem 79: 699-712.
30. Pannaccione A, Secondo A, Scorziello A, Calì G, Taglialatela M, et al. (2005) Nuclear factor-kappaB activation by reactive oxygen species mediates voltage-gated K+ current enhancement by neurotoxic beta-amyloid peptides in nerve growth factor-differentiated PC-12 cells and hippocampal neurones. J Neurochem 94: 572-86.
31. Yu SP (2003) Regulation and critical role of potassium homeostasis in apoptosis. Prog Neurobiol 70: 363-86.
32. Pannaccione A, Boscia F, Scorziello A, Adornetto A, Castaldo P, et al. (2007) Up-regulation and increased activity of KV3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol Pharmacol 72: 665-73.
33. Choi E, Abbott GW (2007) The MiRP2-Kv3.4 potassium channel: muscling in on Alzheimer's disease. Mol Pharmacol 72: 499-501.
34. Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, et al. (2006) Amyloid beta peptide as a physiological modulator of neuronal A′-type K+ current. Neurobiol Aging 27: 1673-83.
35. Pan Y, Xu X, Tong X, Wang X (2004) Messenger RNA and protein expression analysis of voltage-gated potassium channels in the brain of Abeta(25-35)-treated rats. J Neurosci Res 77: 94-9.
36. Etcheberrigaray R, Ito E, Oka K, Tofel-Grehl B, Gibson GE, et al. (1993) Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc Natl Acad Sci U S A 90: 8209-8213.
37. De Silva A, Aronson JK, Grahame-Smith DG, Jobst KA, Smith AD (1998) Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet 352: 1590-1593.
38. Ikeda M, Dewar D, McCulloch J (1991) Selective reduction of [125I]apamin binding sites in Alzheimer hippocampus: a quantitative autoradiographic study. Brain Res 567: 51-56.
39. Alkon DL (1999) Ionic conductance determinants of synaptic memory nets and their implications for Alzheimer's disease. J Neurosci Res 58: 24-32.
40. Poulopoulou C, Markakis I, Davaki P, Tsaltas E, Rombos A, et al. (2010) Aberrant modulation of a delayed rectifier potassium channel by glutamate in Alzheimer's disease. Neurobiol Dis 37: 339-48.
41. Pieri M, Amadoro G, Carunchio I, Ciotti MT, Quaresima S, et al. (2010) SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology 58: 268-76.
42. Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates (Academic San Diego).
43. Roozendaal B, Griffith QK, Buranday J, De Quervain DJ, McGaugh JL (2003) The hippocampus mediates glucocorticoid-induced impairment of spatial memory retrieval: Dependence on the basolateral amygdala. Proc Natl Acad Sci U S A 100: 1328-1333.
44. Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, et al. (2009) Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Nat Acad Sci U S A 106: 8027-31.
45. Zhou M, Suszkiw JB (2004) Nicotine attenuates spatial learning deficits induced in the rat by perinatal lead exposure. Brain Res 999: 142-147.
46. Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, et al. (2002) Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75. Neuroscience 115: 1089-108.
47. D'Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 36: 60-90.
48. Morris RG (2001) Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 356: 1453-65.
49. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-17.
50. Sexton CE, Mackay CE, Lonie JA, Bastin ME, Terrière E, et al. (2010) MRI correlates of episodic memory in Alzheimer's disease, mild cognitive impairment, and healthy aging. Psychiatry Res 184: 57-62
51. Espinosa A, Alegret M, Valero S, Vinyes-Junqué G, Hernández I, et al. (2013) A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis 34: 769-80.
52. Frisch C, Nikolaus S, Huston JP (1994) Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. Behav Neural Biol 62: 110-20.
53. Sprick U, Hasenöhrl RU, Krauth J, Klapdor K, Huston JP (1996) Effects of chronic substance P treatment and intracranial fetal grafts on learning after hippocampal kainic acid lesions. Peptides 17: 275-85.
54. Chappa AK, Audus KL, Lunte SM (2006) Characteristics of substance P transport across the blood-brain barrier. Pharm Res 23: 1201-08.
55. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, et al. (2001) Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse b-amyloid deposits but do not form plaques. Proc Natl Acad Sci U S A 98: 14675-14680.
56. Richardson JC, Kendal CE, Anderson R, Priest F, Gower E, et al. (2003) Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 122: 213-228.
57. Zhang W, Bai M, Xi Y, Hao J, Liu L, et al. (2012) Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 52: 1443-52.
58. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
59. Kawas CH, Corrada MM (2006) Alzheimer's and dementia in the oldest-old: a century of challenges. Curr Alzheimer Res 3: 411-419.
60. Marolda R, Ciotti MT, Matrone C, Possenti R, Calissano P, et al. (2012) Substance P activates ADAM9 mRNA expression and induces α-secretase- mediated amyloid precursor protein cleavage. Neuropharmacology 62: 1954-63.
61. Blunck R, Batulan Z (2012) Mechanism of electromechanical coupling in voltage-gated potassium channels. Front Pharmacol 3: 166.
62. Severini C, Zona C (2006) Tachykinins and excitotoxicity in cerebellar granule cells. Cerebellum 5: 232-237.
63. Meiri N, Ghelardini C, Tesco G, Galeotti N, Dahl D, et al. (1997) Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat. Proc Natl Acad Sci U S A 4: 4430-4
64. Kourrich S, Mourre C, Soumireau-Mourat B (2001) Kaliotoxin, a KV1.1 and KV1.3 channel blocker, improves associative learning in rats. Behav Brain Res 120: 35-46.